Evaluation of Meningococcal Serogroup C Conjugate Vaccine Programs in Canadian Children: Interim Analysis

Vaccine. 2012 Jun 8;30(27):4023-7. doi: 10.1016/j.vaccine.2012.04.034. Epub 2012 Apr 23.

Abstract

Background: To assess antibody titers afforded by meningococcal C- (MenC) tetanus toxoid conjugate vaccine at 12 months of age in three different immunization schedules.

Methods: This prospective study included three similar cohorts of healthy infants from 1-dose, 2-dose and 3-dose MenC infant immunization programs. Infants were enrolled at 12 months of age and given the final scheduled dose of MenC-tetanus toxoid conjugate vaccine with sera collected prior to and 1 month after the vaccination. Serum bactericidal activity (SBA) titers ≥ 1:8 were considered protective.

Results: Before the 12 month dose, participants had significantly different protective titers according to the number of prior doses received: 100% (95% CI 97.6-100%) of infants who had 2 prior doses (at 2 and 4 months) were protected compared to 84.0% (76.7-89.3%) of participants with one dose (at 2 months) and 27.6% (21.0-35.4%) of unvaccinated infants. All subjects were protected after the 12 month MenC dose, but titers were higher with prior priming.

Conclusions: Two MenC doses given in infancy afford optimal protection during the first year of life; however, substantial protection was seen after one dose at 2 months.

Trial registration: ClinicalTrials.gov NCT00936962.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial / blood
  • Blood Bactericidal Activity
  • Canada / epidemiology
  • Cohort Studies
  • Female
  • Humans
  • Infant
  • Male
  • Meningococcal Infections / epidemiology*
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines / administration & dosage*
  • Meningococcal Vaccines / immunology*
  • Neisseria meningitidis, Serogroup C / immunology*
  • Prospective Studies
  • Vaccines, Conjugate / administration & dosage
  • Vaccines, Conjugate / immunology

Substances

  • Antibodies, Bacterial
  • Meningococcal Vaccines
  • Vaccines, Conjugate

Associated data

  • ClinicalTrials.gov/NCT00936962